vs
Amneal Pharmaceuticals, Inc.（AMRX）与DOCUSIGN, INC.（DOCU）财务数据对比。点击上方公司名可切换其他公司
DOCUSIGN, INC.的季度营收约是Amneal Pharmaceuticals, Inc.的1.1倍（$818.4M vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 10.2%，领先0.6%），DOCUSIGN, INC.同比增速更快（8.4% vs 3.9%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
DocuSign是总部位于美国加利福尼亚州旧金山的软件企业，为各类机构提供多设备支持的电子协议管理及电子签名相关产品。截至2025年，公司在180个国家拥有约170万客户，其处理的签名符合美国ESIGN法案、欧盟eIDAS法规要求，满足欧盟高级及合格签名标准。
AMRX vs DOCU — 直观对比
营收规模更大
DOCU
是对方的1.1倍
$722.5M
营收增速更快
DOCU
高出4.5%
3.9%
净利率更高
AMRX
高出0.6%
10.2%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $818.4M |
| 净利润 | $78.0M | $83.7M |
| 毛利率 | 44.3% | 79.2% |
| 营业利润率 | 19.6% | 10.4% |
| 净利率 | 10.8% | 10.2% |
| 营收同比 | 3.9% | 8.4% |
| 净利润同比 | 410.5% | 34.1% |
| 每股收益（稀释后） | $0.19 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXDOCU
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $818.4M | ||
| Q3 25 | $784.5M | $800.6M | ||
| Q2 25 | $724.5M | $763.7M | ||
| Q1 25 | $695.4M | — | ||
| Q4 24 | $730.5M | — | ||
| Q3 24 | $702.5M | — | ||
| Q2 24 | $701.8M | — |
净利润AMRXDOCU
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $83.7M | ||
| Q3 25 | $2.4M | $63.0M | ||
| Q2 25 | $22.4M | $72.1M | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $-31.1M | — | ||
| Q3 24 | $-156.0K | — | ||
| Q2 24 | $6.0M | — |
毛利率AMRXDOCU
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 79.2% | ||
| Q3 25 | 34.9% | 79.3% | ||
| Q2 25 | 39.5% | 79.4% | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — |
营业利润率AMRXDOCU
| Q1 26 | 19.6% | — | ||
| Q4 25 | 13.8% | 10.4% | ||
| Q3 25 | 9.0% | 8.1% | ||
| Q2 25 | 15.4% | 7.9% | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — |
净利率AMRXDOCU
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 10.2% | ||
| Q3 25 | 0.3% | 7.9% | ||
| Q2 25 | 3.1% | 9.4% | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | -4.3% | — | ||
| Q3 24 | -0.0% | — | ||
| Q2 24 | 0.9% | — |
每股收益（稀释后）AMRXDOCU
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.40 | ||
| Q3 25 | $0.01 | $0.30 | ||
| Q2 25 | $0.07 | $0.34 | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.10 | — | ||
| Q3 24 | $0.00 | — | ||
| Q2 24 | $0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $197.7M | $583.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $2.0B |
| 总资产 | $3.5B | $4.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXDOCU
| Q1 26 | $197.7M | — | ||
| Q4 25 | $282.0M | $583.3M | ||
| Q3 25 | $201.2M | $600.0M | ||
| Q2 25 | $71.5M | $657.4M | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — |
总债务AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $2.0B | ||
| Q3 25 | $-109.5M | $2.0B | ||
| Q2 25 | $-112.1M | $2.0B | ||
| Q1 25 | $-131.7M | — | ||
| Q4 24 | $-109.3M | — | ||
| Q3 24 | $-93.4M | — | ||
| Q2 24 | $-57.5M | — |
总资产AMRXDOCU
| Q1 26 | $3.5B | — | ||
| Q4 25 | $3.7B | $4.0B | ||
| Q3 25 | $3.6B | $3.9B | ||
| Q2 25 | $3.4B | $3.9B | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.5B | — | ||
| Q2 24 | $3.5B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $290.3M |
| 自由现金流经营现金流 - 资本支出 | — | $262.9M |
| 自由现金流率自由现金流/营收 | — | 32.1% |
| 资本支出强度资本支出/营收 | — | 3.3% |
| 现金转化率经营现金流/净利润 | — | 3.47× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $290.3M | ||
| Q3 25 | $118.5M | $246.1M | ||
| Q2 25 | $83.8M | $251.4M | ||
| Q1 25 | $7.4M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $39.7M | — |
自由现金流AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $262.9M | ||
| Q3 25 | $106.2M | $217.6M | ||
| Q2 25 | $61.0M | $227.8M | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 32.1% | ||
| Q3 25 | 13.5% | 27.2% | ||
| Q2 25 | 8.4% | 29.8% | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 3.3% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 3.2% | 3.1% | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXDOCU
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 3.47× | ||
| Q3 25 | 50.00× | 3.91× | ||
| Q2 25 | 3.74× | 3.49× | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
暂无分部数据
DOCU
| Subscription And Circulation | $801.0M | 98% |
| Professional Services And Other | $17.4M | 2% |
